DE3433328A1 - Pharmazeutische zusammensetzung fuer die therapie peripherer arteriopathien - Google Patents
Pharmazeutische zusammensetzung fuer die therapie peripherer arteriopathienInfo
- Publication number
- DE3433328A1 DE3433328A1 DE19843433328 DE3433328A DE3433328A1 DE 3433328 A1 DE3433328 A1 DE 3433328A1 DE 19843433328 DE19843433328 DE 19843433328 DE 3433328 A DE3433328 A DE 3433328A DE 3433328 A1 DE3433328 A1 DE 3433328A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- therapy
- arteriopathies
- defibrotide
- peripheral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 200000000007 Arterial disease Diseases 0.000 claims abstract description 14
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960004120 defibrotide Drugs 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 241000982080 Trophis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000003558 thrombophilic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22855/83A IT1170214B (it) | 1983-09-12 | 1983-09-12 | Composizione farmaceutica per la cura delle arteriopatie periferiche |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3433328A1 true DE3433328A1 (de) | 1985-03-28 |
| DE3433328C2 DE3433328C2 (enExample) | 1993-08-05 |
Family
ID=11201215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843433328 Granted DE3433328A1 (de) | 1983-09-12 | 1984-09-11 | Pharmazeutische zusammensetzung fuer die therapie peripherer arteriopathien |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5081109A (enExample) |
| EP (1) | EP0137543B1 (enExample) |
| JP (1) | JPH0647545B2 (enExample) |
| AT (1) | ATE55695T1 (enExample) |
| BE (1) | BE900564A (enExample) |
| CH (1) | CH661870A5 (enExample) |
| DE (1) | DE3433328A1 (enExample) |
| IT (1) | IT1170214B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0819468A1 (de) | 1996-03-18 | 1998-01-21 | Krupp VDM GmbH | Katalysator zur Oxidation von Abwasserverunreinigungen mittels Persäuren |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| HK1044896A1 (zh) * | 1997-04-28 | 2002-11-08 | Burcoglu Arsinur | 治疗hiv感染和与之有关的继发感染的方法 |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| MX2007010754A (es) * | 2005-03-03 | 2007-11-07 | Gentium Spa | Defibrotide y/u oligodeoxiribonucleotidos para tratar tumores dependientes de angiogenesis. |
| EP1891952B1 (en) * | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmaceutical composition of olmesartan medoxomil |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| KR20150044877A (ko) | 2012-06-22 | 2015-04-27 | 젠티엄 에스피에이 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| KR20200121780A (ko) | 2017-08-03 | 2020-10-26 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 높은 농도에서 핵산을 포함하는 제제 |
| BR112020020865A2 (pt) | 2018-04-12 | 2021-01-19 | Jazz Pharmaceuticals, Inc. | Defibrotida para prevenção e tratamento da síndrome de liberação de citocinas e neurotoxicidade associadas à imunodepleção |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| EP4110287A1 (en) | 2020-02-28 | 2023-01-04 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| US20230086833A1 (en) | 2020-04-17 | 2023-03-23 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US4485105A (en) * | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| US4416877A (en) * | 1979-02-13 | 1983-11-22 | Symphar S.A. | Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds |
| GB2043072B (en) * | 1979-02-13 | 1983-11-23 | Symphar Sa | Diphosphonate compounds |
| JPS5675474A (en) * | 1979-11-22 | 1981-06-22 | Chugai Pharmaceut Co Ltd | Nicotinamide derivative and medicine containing the same |
| US4351950A (en) * | 1980-01-02 | 1982-09-28 | Warner-Lambert Company | Anti-arteriosclerotic agents |
| US4450272A (en) * | 1982-05-06 | 1984-05-22 | American Cyanamid Company | Antiatherosclerotic 1-piperazine-thicarboxamides |
| IT1167197B (it) * | 1983-07-25 | 1987-05-13 | Bellon Roger Schoum Rbs Pharma | Impiego della fenpiramina quale farmaco antiaggregante piastrinico,vasodilatatore,antitrombotico e antianginoso |
| IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
-
1983
- 1983-09-12 IT IT22855/83A patent/IT1170214B/it active
-
1984
- 1984-09-07 EP EP84201287A patent/EP0137543B1/en not_active Expired - Lifetime
- 1984-09-07 CH CH4280/84A patent/CH661870A5/it not_active IP Right Cessation
- 1984-09-07 AT AT84201287T patent/ATE55695T1/de active
- 1984-09-11 DE DE19843433328 patent/DE3433328A1/de active Granted
- 1984-09-12 BE BE0/213641A patent/BE900564A/fr not_active IP Right Cessation
- 1984-09-12 JP JP59191391A patent/JPH0647545B2/ja not_active Expired - Lifetime
-
1988
- 1988-07-05 US US07/218,514 patent/US5081109A/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Thrombosis Research, 30, S. 1-11 (1983) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0819468A1 (de) | 1996-03-18 | 1998-01-21 | Krupp VDM GmbH | Katalysator zur Oxidation von Abwasserverunreinigungen mittels Persäuren |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0647545B2 (ja) | 1994-06-22 |
| ATE55695T1 (de) | 1990-09-15 |
| DE3433328C2 (enExample) | 1993-08-05 |
| JPS6169722A (ja) | 1986-04-10 |
| EP0137543B1 (en) | 1990-08-22 |
| EP0137543A3 (en) | 1987-09-02 |
| CH661870A5 (it) | 1987-08-31 |
| US5081109A (en) | 1992-01-14 |
| IT1170214B (it) | 1987-06-03 |
| IT8322855A0 (it) | 1983-09-12 |
| BE900564A (fr) | 1985-01-02 |
| EP0137543A2 (en) | 1985-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3433328C2 (enExample) | ||
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE69632743T2 (de) | Verfahren zur regulierung des vagaltonus | |
| DE2732175C2 (de) | Oxytocin-Strukturanaloga und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE2934718A1 (de) | Loesung fuer die intravenoese verabreichung | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| DE69917796T2 (de) | Decursin-enthaltende pharmazeutische zusammensetzungen | |
| DE69004532T2 (de) | Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen. | |
| DE3317692A1 (de) | Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen | |
| DE69705110T2 (de) | Topische pharmazeutische zusammensetzungen, welche heparin enthalten | |
| DE2803869A1 (de) | Injizierbare embolisations- und okklusionsloesung | |
| DE3152319T1 (enExample) | ||
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE19529909C2 (de) | Wässrige Spüllösung | |
| DE19734693A1 (de) | Verwendung von Cariporide als Inhibitor des zellulären NA+/H+-Exchangers (NHE) zur Herstellung eines Medikaments zur Behandlung von cardialen und nichtcardialen Krankheiten | |
| EP0294538A2 (de) | Verwendung von Nigerizin zur Herstellung eines Mittels zur Behandlung von Virus-Erkrankungen | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| EP0032564A1 (de) | Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest | |
| Nalefski et al. | The use of crystalline visammin in the treatment of angina pectoris | |
| EP0363355A1 (de) | Arzneimittel, enthaltend lokalanästhetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen | |
| EP0278013A1 (de) | Antihypoxisches Mittel | |
| DE2633891A1 (de) | Neues salz der alpha-methylbenzoyl- 5-thiophen-2-essigsaeure, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen | |
| CH644374A5 (en) | Water-soluble hydroxyflavone ethers and medicaments containing them | |
| DE69626691T2 (de) | Komponente b als wundheilendes mittel | |
| DE3203011C2 (de) | Verwendung von 2-(3-Dimethylaminopropyl)-5,9-Dimethyl-4,8-Decadiensäure zur Behandlung von Herzerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |